BCT-100 is under clinical development by Bio-Cancer Treatment International and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BCT-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BCT-100 (PEG-BCT-100) is under development for the treatment of hepatocellular carcinoma, melanoma, hormone refractory prostate cancer, relapsed/refractory acute lymphoblastic leukemia, relapsed/refractory acute myeloid leukemia (AML), neuroblastoma, sarcoma, and high-grade gliomas. The drug candidate is administered through the intravenous route. It is a pegylated recombinant human arginase in phosphate saline buffer. It acts by targeting arginine. The drug candidate is developed using chemical synthetic technology. It was also under development for the treatment of relapsed/refractory lymphoma, renal cell carcinoma, lung adenocarcinoma, and astrocytoma.
Bio-Cancer Treatment International overview
Bio-Cancer Treatment International (BCT) is a clinical-stage biopharmaceutical company that offers research and development of biologics. The company’s products comprise BCT-100 and BCT-200. Its BCT-100 provides pegylated recombinant human arginase being developed for arginine depletion therapy in arginine auxotrophic cancers. BCT’s BCT-200 is a modification of BCT-100 with alterations to the amino acid sequence being developed for arginine depletion therapy in autoimmune disorders and other potential indications. The company develops innovative biologics for the treatment of human malignancies and auto-immune disorders. It has its presence in Shanghai and Hong Kong. BCT is headquartered in Hong Kong.
For a complete picture of BCT-100’s drug-specific PTSR and LoA scores, buy the report here.